

Revision date: 04-Apr-2015

Version: 1.5

Page 1 of 12

### 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING Product Identifier

Material Name: Tramadol Hydrochloride Capsules

Trade Name:Nobligan; TramalChemical Family:Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against Intended Use: Pharmaceutical product used as analgesic

Details of the Supplier of the Safety Data Sheet Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-800-879-3477

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: pfizer-MSDS@pfizer.com

## 2. HAZARDS IDENTIFICATION

## Classification of the Substance or Mixture

GHS - Classification

Acute Oral Toxicity: Category 4

### EU Classification:

EU Indication of danger: Harmful

EU Risk Phrases:

R22 - Harmful if swallowed.

### Label Elements

Signal Word:	Warning
Hazard Statements:	H302 - Harmful if swallowed

Precautionary Statements:	P264 - Wash hands thoroughly after handling P270 - Do not eat, drink or smoke when using this product P301+ P312 - IF SWALLOWED: Call a POISON CENTRE or doctor/physician if you feel unwell
	P330 - Rinse mouth P501 - Dispose of contents/container in accordance with all local and national regulations

Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161 Emergency telephone number: International CHEMTREC (24 hours): +1-703-527-3887

### Material Name: Tramadol Hydrochloride Capsules Revision date: 04-Apr-2015

Page 2 of 12 Version: 1.5



Other Hazards Australian Hazard Classification (NOHSC):

Note:

No data available Hazardous Substance. Non-Dangerous Goods.

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## **3. COMPOSITION / INFORMATION ON INGREDIENTS**

#### Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS	EU Classification	GHS Classification	%
		List		Classification	
Tramadol Hydrochloride	73806-49-2	Not Listed	Xn; R22	Acute Tox.3 (H301)	50 mg***
Microcrystalline cellulose	9004-34-6	232-674-9	Not Listed	Not Listed	*
Iron oxide	1309-37-1	215-168-2	Not Listed	Not Listed	*
Magnesium stearate	557-04-0	209-150-3	Not Listed	Not Listed	*
Colloidal silicon dioxide	7631-86-9	231-545-4	Not Listed	Not Listed	*
Titanium dioxide	13463-67-7	236-675-5	Not Listed	Not Listed	*
Sodium lauryl sulfate	151-21-3	205-788-1	Not Listed	Not Listed	*

Ingredient	CAS Number	EU	EU Classification	GHS	%
		EINECS/ELINCS		Classification	
		List			
Iron Hydroxide	11113-66-9	234-346-0	Not Listed	Not Listed	*
Gelatin	9000-70-8	232-554-6	Not Listed	Not Listed	*
Sodium starch glycolate	9063-38-1	Not Listed	Not Listed	Not Listed	*
Indigotin I (E 132)	482-89-3	207-586-9	Not Listed	Not Listed	*

**Additional Information:** 

\*\*\* per tablet/capsule/lozenge/suppository

\* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

### For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

Description of First Aid Measures Eye Contact:	Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.
Skin Contact:	Wash skin with soap and water. If irritation occurs or persists, get medical attention.

### Material Name: Tramadol Hydrochloride Capsules Revision date: 04-Apr-2015

Ingestion:	Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.			
Inhalation:	Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.			
Most Important Symptoms and Effect Symptoms and Effects of Exposure: Medical Conditions Aggravated by Exposure:	fects, Both Acute and Delayed For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information. None known			
Indication of the Immediate Medical Notes to Physician:	Attention and Special Treatment Needed None			
5. FIRE FIGHTING MEASURES	6			
Extinguishing Media:	Extinguish fires with CO2, extinguishing powder, foam, or water.			
Special Hazards Arising from the Substance or Mixture         Hazardous Combustion       Formation of toxic gases is possible during heating or fire.         Products:				
Fire / Explosion Hazards:	Not applicable			
Advice for Fire-Fighters During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.				
6. ACCIDENTAL RELEASE MEASURES				
Personal Precautions, Protective Equipment and Emergency Procedures Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.				
Environmental Precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.				
Methods and Material for Containment and Cleaning Up         Measures for Cleaning /       Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.				

Additional Consideration for	Non-essential personnel should be evacuated from affected area. Report emergency	
Large Spills:	situations immediately. Clean up operations should only be undertaken by trained personnel.	

## 7. HANDLING AND STORAGE

### **Precautions for Safe Handling**

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

### Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions:	Store as directed by product packaging.
Specific end use(s):	Pharmaceutical drug product

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

### **Control Parameters**

Refer to available public information for specific member state Occupational Exposure Limits.

Mioro	anystalling colluloso	
WICTO	crystalline cellulose ACGIH Threshold Limit Value (TWA)	10 mg/m <sup>3</sup>
	Australia TWA	10 mg/m <sup>3</sup>
	Belgium OEL - TWA	10 mg/m <sup>3</sup>
	Estonia OEL - TWA	10 mg/m <sup>3</sup>
	France OEL - TWA	10 mg/m <sup>3</sup>
	Ireland OEL - TWA	10 mg/m <sup>3</sup>
	Ireland OEL - TWAS	$4 \text{ mg/m}^3$
	Latvia OEL - TWA	$2 \text{ mg/m}^3$
	OSHA - Final PELS - TWAs:	15 mg/m <sup>3</sup>
	Portugal OEL - TWA	10 mg/m <sup>3</sup>
	Romania OEL - TWA	10 mg/m <sup>3</sup>
	Russia OEL - TWA	$6 \text{ mg/m}^3$
	Spain OEL - TWA	10 mg/m <sup>3</sup>
	Switzerland OEL -TWAS	$3 \text{ mg/m}^3$
	Vietnam OEL - TWAS	10 mg/m <sup>3</sup>
	Vietnam OEL - TWAS	$5 \text{ mg/m}^3$
		5 mg/m
Iron c	oxide	
	ACGIH Threshold Limit Value (TWA)	5 mg/m <sup>3</sup>
	Australia TWA	5 mg/m <sup>3</sup>
		10 mg/m <sup>3</sup>
	Austria OEL - MAKs	5 mg/m <sup>3</sup>
		10 mg/m <sup>3</sup>
	Belgium OEL - TWA	2 ppm
		5 mg/m³
	Bulgaria OEL - TWA	5.0 mg/m <sup>3</sup>
	Denmark OEL - TWA	3.5 mg/m <sup>3</sup>
	Estonia OEL - TWA	3.5 mg/m <sup>3</sup>
	Finland OEL - TWA	5 mg/m³
	France OEL - TWA	5 mg/m³
	Greece OEL - TWA	10 mg/m <sup>3</sup>
	Hungary OEL - TWA	6 mg/m³
	Ireland OEL - TWAs	5 mg/m <sup>3</sup>
		10 mg/m <sup>3</sup>
		4 mg/m <sup>3</sup>
	Lithuania OEL - TWA	3.5 mg/m <sup>3</sup>
	OSHA - Final PELS - TWAs:	10 mg/m <sup>3</sup>
		15 mg/m <sup>3</sup>
	Poland OEL - TWA	5 mg/m <sup>3</sup>
	Portugal OEL - TWA	5 mg/m <sup>3</sup>
	Romania OEL - TWA	$5 \text{ mg/m}^3$
	Russia OEL - TWA	$6 \text{ mg/m}^3$
	Slovakia OEL - TWA	1.5 mg/m <sup>3</sup>
	Spain OEL - TWA	5 mg/m <sup>3</sup>
	Sweden OEL - TWAs	$3.5 \text{ mg/m}^3$
	Switzerland OEL -TWAs	3 mg/m <sup>3</sup>
	Vietnam OEL - TWAs	5 mg/m <sup>3</sup>

Material Name: Tramadol Hydrochloride Capsules Revision date: 04-Apr-2015 Page 5 of 12 Version: 1.5

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Magnesium stearate	
ACGIH Threshold Limit Value (TWA)	10 mg/m <sup>3</sup>
Lithuania OEL - TWA	5 mg/m <sup>3</sup>
Sweden OEL - TWAs	5 mg/m <sup>3</sup>
	0 mg/m
Colloidal silicon dioxide	
Australia TWA	2 mg/m <sup>3</sup>
Austria OEL - MAKs	4 mg/m <sup>3</sup>
	0.3 mg/m <sup>3</sup>
Czech Republic OEL - TWA	0.1 mg/m <sup>3</sup>
	4.0 mg/m <sup>3</sup>
Estonia OEL - TWA	2 mg/m <sup>3</sup>
Finland OEL - TWA	5 mg/m <sup>3</sup>
Germany - TRGS 900 - TWAs	4 mg/m <sup>3</sup>
Germany (DFG) - MAK	4 mg/m <sup>3</sup>
Ireland OEL - TWAs	6 mg/m <sup>3</sup>
	2.4 mg/m <sup>3</sup>
Latvia OEL - TWA	1 mg/m <sup>3</sup>
OSHA - Final PELs - Table Z-3 Mineral D:	20 mppcf
Slovekie OEL TWA	Listed
Slovakia OEL - TWA Switzerland OEL -TWAs	4.0 mg/m <sup>3</sup> 4 mg/m <sup>3</sup>
Switzendilu OEL - I WAS	$4 \text{ mg/m}^3$
	0.0 mg/m
Titanium dioxide	
ACGIH Threshold Limit Value (TWA)	10 mg/m <sup>3</sup>
ACGIH OELs - Notice of Intended Changes	Listed
Australia TWA	10 mg/m <sup>3</sup>
Austria OEL - MAKs	5 mg/m <sup>3</sup>
Belgium OEL - TWA	10 mg/m <sup>3</sup>
Bulgaria OEL - TWA	10.0 mg/m <sup>3</sup>
Denmark OEL - TWA	6 mg/m³
Estonia OEL - TWA	5 mg/m³
France OEL - TWA	10 mg/m <sup>3</sup>
Greece OEL - TWA	10 mg/m <sup>3</sup>
	5 mg/m <sup>3</sup>
Ireland OEL - TWAs	10 mg/m <sup>3</sup>
	$4 \text{ mg/m}^3$
Latvia OEL - TWA Lithuania OEL - TWA	10 mg/m³ 5 mg/m³
OSHA - Final PELS - TWAS:	
Poland OEL - TWA	15 mg/m³ 10.0 mg/m³
Portugal OEL - TWA	10.0 mg/m <sup>3</sup>
Romania OEL - TWA	10 mg/m <sup>3</sup>
Russia OEL - TWA	10 mg/m <sup>3</sup>
Spain OEL - TWA	10 mg/m <sup>3</sup>
Sweden OEL - TWAS	5 mg/m <sup>3</sup>
Switzerland OEL -TWAS	3 mg/m <sup>3</sup>
Vietnam OEL - TWAs	6 mg/m <sup>3</sup>
	5 mg/m <sup>3</sup>
	0
Sodium lauryl sulfate	
	$0.3 \text{ ma/m}^3$

Pfizer OEL TWA-8 Hr:

0.3 mg/m<sup>3</sup>

### Material Name: Tramadol Hydrochloride Capsules Revision date: 04-Apr-2015

Page 6 of 12 Version: 1.5

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

### Tramadol Hydrochloride

**Pfizer Occupational Exposure** OEB 2 (control exposure to the range of 100ug/m<sup>3</sup> to < 1000ug/m<sup>3</sup>) **Band (OEB):** 

Expo	osure Controls	
·	Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep air contamination levels below the exposure limits or within the OEB range listed above in this section.
	Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
	Hands:	Not required for the normal use of this product. Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
	Eyes:	Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is possible.
	Skin:	Not required for the normal use of this product. Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
	Respiratory protection:	Not required for the normal use of this product. Whenever excessive air contamination (dust, mist, vapor) is generated, respiratory protection, with appropriate protection factors, should be used to minimize exposure.

## 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Capsule	Color:	No data available.
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solvent Solubility: Water Solubility: pH: Melting/Freezing Point (°C): Boiling Point (°C): Partition Coefficient: (Method, pH, I Tramadol Hydrochloride Predicted 7 Log P 1.34 Iron Hydroxide No data available Microcrystalline cellulose No data available Iron oxide No data available Magnesium stearate No data available Gelatin No data available Titanium dioxide	No data available No data available No data available No data available No data available. Endpoint, Value)		

Material Name: Tramadol Hydrochloride Capsules Revision date: 04-Apr-2015

9. PHYSICAL AND CHEMICAL PROPERTIES

No data available Sodium starch glycolate No data available Sodium lauryl sulfate No data available Indigotin I (E 132) No data available Colloidal silicon dioxide No data available Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s):No data availableVapor Pressure (kPa):No data availableVapor Density (g/ml):No data availableRelative Density:No data availableViscosity:No data available

Flammablity: Autoignition Temperature (Solid) (°C): Flammability (Solids): Flash Point (Liquid) (°C): Upper Explosive Limits (Liquid) (% by Vol.): Lower Explosive Limits (Liquid) (% by Vol.):

### No data available No data available No data available No data available No data available

## **10. STABILITY AND REACTIVITY**

Reactivity:	No data available
Chemical Stability:	Stable under normal conditions of use.
Possibility of Hazardous Reactions	
Oxidizing Properties:	No data available
Conditions to Avoid:	None known
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition	No data available
Products:	

### 11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects	6
General Information:	There are no data for this formulation. The information included in this section describes the potential hazards of the individual ingredients.
Short Term:	May cause eye irritation; May cause skin irritation. (based on components) May be harmful if swallowed. (based on animal data).
Long Term:	Use of this drug is habit forming. Addiction may occur.
Known Clinical Effects:	Ingestion of this material may cause effects similar to those seen in clinical use including dry mouth, drowsiness, headache, dizziness, nausea, vomiting, weakness, anxiety, and dilated pupils. Cases of severe overdose may lead to respiratory depression, hypotension, coma, convulsions, cardiac arrhythmia, and tachycardia.

### Acute Toxicity: (Species, Route, End Point, Dose)

### **Tramadol Hydrochloride**

Rat Oral LD50 228 mg/kg Rat Para-periosteal LD50 57.6mg/kg

# Material Name: Tramadol Hydrochloride Capsules Revision date: 04-Apr-2015

**11. TOXICOLOGICAL INFORMATION** 

RatSubcutaneousLD50286mg/kgMouseOralLD50270mg/kgMouseIntravenousLD5060.4mg/kg

### Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg Rabbit Dermal LD50 > 2000 mg/kg

### **Magnesium stearate**

Rat Oral LD50 > 2000 mg/kg Rat Inhalation LC50 > 2000 mg/m<sup>3</sup>

### **Titanium dioxide**

Rat Oral LD50 > 7500 mg/kg Rat Subcutaneous LD50 50 mg/kg

### Sodium lauryl sulfate

Rat Oral LD50 1288 mg/kg Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

### Irritation / Sensitization: (Study Type, Species, Severity)

### Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating Eye Irritation Rabbit Non-irritating

### Sodium lauryl sulfate

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild Moderate Skin Sensitization - GPMT Guinea Pig Negative Skin Sensitization - LLNA Mouse Negative

### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

### **Tramadol Hydrochloride**

6 Week(s) Rat Oral 20 mg/kg/day NOAEL 26 Week(s) Dog Oral 10 mg/kg/day NOAEL

## Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

### Tramadol Hydrochloride

Reproductive & Fertility Rat Oral 50-75 mg/kg NOAEL Fertility Embryo / Fetal Development Oral 25 mg/kg Maternal Toxicity, Fetotoxicity Rat LOAEL Embryo / Fetal Development Rabbit Oral 75 mg/kg LOAEL Maternal Toxicity, Fetotoxicity Embryo / Fetal Development Maternal Toxicity, Fetotoxicity Mouse Oral 120 mg/kg LOAEL Peri-/Postnatal Development LOAEL Maternal Toxicity, Fetotoxicity Rat Oral 50 mg/kg

## Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Tramadol Hydrochloride

## Material Name: Tramadol Hydrochloride Capsules

Revision date: 04-Apr-2015

<b>11. TOXICOLOGICAL INFOR</b>		
	almonella, E. coli Negative	
	Chinese Hamster Ovary (CHO) cells Negative	
In Vivo Micronucleus Mouse Bone Marrow Negative		
In Vitro Micronucleus Rat Positive		
In Vitro Mammalian Cell Mutagenicit	y Mouse Lymphoma Positive	
Sodium lauryl sulfate		
-	almonella Negative	
Dacterial Mutagenicity (Ames)	antonena riegalive	
Carcinogenicity: (Duration, Specie	es, Route, Dose, End Point, Effect(s))	
Tramadol Hydrochloride		
2 Year(s) Mouse Oral 30 mg/kg/day NOEL Not carcinogenic		
2 Year(s) Rat Oral 30 mg	/kg/day NOAEL Not carcinogenic	
Carcinogen Status:	See below	
Iron oxide		
IARC:	Group 3 (Not Classifiable)	
IARC:	Gloup 5 (Not Classifiable)	
Titanium dioxide		
IARC:	Group 2B (Possibly Carcinogenic to Humans)	
Colloidal silicon dioxide		
IARC:	Group 3 (Not Classifiable)	

## 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

### **Toxicity:**

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Sodium lauryl sulfate Oncorhynchus mykiss (Rainbow Trout) LC50 96 Hours 3.6 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential: Partition Coefficient: (Method, pH, Endpoint, Value) Tramadol Hydrochloride Predicted 7 Log P 1.34

Mobility in Soil: No data available

Material Name: Tramadol Hydrochloride Capsules Revision date: 04-Apr-2015 Page 10 of 12 Version: 1.5

### **13. DISPOSAL CONSIDERATIONS**

Waste Treatment Methods:Dispose of waste in accordance with all applicable laws and regulations. Member State<br/>specific and Community specific provisions must be considered. Considering the relevant<br/>known environmental and human health hazards of the material, review and implement<br/>appropriate technical and procedural waste water and waste disposal measures to prevent<br/>occupational exposure and environmental release. It is recommended that waste minimization<br/>be practiced. The best available technology should be utilized to prevent environmental<br/>releases. This may include destructive techniques for waste and wastewater.

### **14. TRANSPORT INFORMATION**

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

## **15. REGULATORY INFORMATION**

**Canada - WHMIS: Classifications** 

Class D, Division 1, Subdivision B

WHMIS hazard class:

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Tramadol Hydrochloride	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed
Iron Hydroxide	
<b>CERCLA/SARA 313 Emission reporting</b>	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	234-346-0
Microcrystalline cellulose	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex XVII - Restrictions on Certain Dangerous Substances:	Use restricted. See item 9[f]. powder

Material Name: Tramadol Hydrochloride Capsules Revision date: 04-Apr-2015 Page 11 of 12 Version: 1.5

15. REGULATORY INFORMATION	
EU EINECS/ELINCS List	232-674-9
Iron oxide	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	215-168-2
Magnesium stearate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3
<b>-</b>	
Colloidal silicon dioxide	Not Listed
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS): EU EINECS/ELINCS List	Present 231-545-4
	201-040-4
Gelatin	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-554-6
Titanium dioxide	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen initial date 9/2/11 airborne, unbound particles of
	respirable size
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	236-675-5
Sodium starch glycolate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS): EU EINECS/ELINCS List	Present Not Listed
EU EINEGJ/ELINGJ LISI	
Sodium lauryl sulfate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling	Schedule 6
for Drugs and Poisons:	

Material Name: Tramadol Hydrochloride Capsules Revision date: 04-Apr-2015 Page 12 of 12 Version: 1.5

EU EINECS/ELINCS List	205-788-1	
ndigotin I (E 132)		
CERCLA/SARA 313 Emission reporting	Not Listed	
California Proposition 65	Not Listed	
Inventory - United States TSCA - Sect. 8(b)	Present	
Australia (AICS):	Present	
EU EINECS/ELINCS List	207-586-9	

## **16. OTHER INFORMATION**

### Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.3; H301 - Toxic if swallowed

Xn - Harmful	
R22 - Harmful if swallowed. <b>Data Sources:</b>	Pfizer proprietary drug development information. Publicly available toxicity information.
Reasons for Revision:	Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 15 - Regulatory Information.
Revision date:	04-Apr-2015 Product Stewardship Hazard Communication
Prepared by:	Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet